Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
World J Surg Oncol. 2011 Jul 13;9:73. doi: 10.1186/1477-7819-9-73.
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
肾集合管癌（CDC）是一种罕见且侵袭性强的恶性肿瘤，起源于远端集合管，已证明对多种全身治疗反应不佳。我们报告了一例转移性 CDC 对多种酪氨酸激酶抑制剂舒尼替尼反应良好的病例，在肺和骨骼转移部位均达到部分缓解。据我们所知，这是首例报道舒尼替尼对 CDC 有治疗活性的病例。鉴于这些发现，前瞻性研究多种酪氨酸激酶抑制剂（特别是舒尼替尼）在转移性 CDC 治疗中的作用是值得的。
